You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希諾生物(06185.HK)CEO料吸入式疫苗助結束新冠疫情大流行
康希諾生物(06185.HK)首席執行官宇學峯預計,吸入式疫苗的療效與注射式疫苗一樣好,有助於結束新冠疫情大流行。 康希諾近日在互動平臺透露,已展開上萬人的吸入用新冠疫苗序貫免疫臨牀試驗,安全性及免疫原性數據顯示,在肌注疫苗裏十分常見的不良反應,如頭疼、疲乏和發熱在吸入疫苗裏發生總量大幅下降,在老年人中下降幅度更大,其中三級的不良反應,如發熱已經下降到百分之零點幾;使用吸入用新冠疫苗序貫加強後28天,針對Omicron活病毒的交叉中和抗體滴度是用滅活疫苗同源加強的22.8倍。 於9月4日,康希諾公告稱,公司研發的吸入用重組新型冠狀病毒疫苗,經國家衛生健康委提出建議,國家藥品監督管理局組織論證同意作爲加強針納入緊急使用。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account